
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is well-positioned for sustained long-term revenue growth as the market for next-generation diagnostic tests continues to expand. With strong sales of its Afirma and Decipher tests, as well as upcoming launches of the Percepta Nasal Swab test and kitted versions of its tests in Europe, the company has a solid foundation for mid-teens or better revenue growth. Additionally, the recent acquisition of C2i Genomics and its TrueMRD test for bladder cancer further expands Veracyte's potential in the rapidly growing market for genomic diagnostics. While there are risks such as weaker sales and margins, the company's strong financials and pipeline indicate a positive outlook for Veracyte's stock.
Bears say
Veracyte is a leading genomic diagnostics company with potential upside from its Decipher and Afirma tests, strong revenue growth potential, and potential for better operating margins and free cash flow. However, it also faces potential downside risks due to weaker sales growth and operating margins, leading to a possible bear case scenario and price target of $24 based on an EV/sales multiple of 2.5x our 2027E sales estimate.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares